{"type":"trials","record":{"id":42053,"source_id":"clinicaltrials-gov","external_id":"NCT06183814","title":"A Study of EXG102-031 in Participants With wAMD","brief_summary":"In neovascular (wet) age-related macular degeneration (wAMD), the macula, or the part of the eye that provides the clear, detailed central vision, is being affected by abnormal blood vessel growth and leakage. This leakage affects the vision over time and can lead to severe blurriness or blinding. EXG102-031 was made to block the extra vessel formation which would lead to less leakage affecting the vision. Before EXG102-031 can be tested for its efficacy (if it makes vision better), it must be tested to see if it is safely tolerated to confirm it can continue to be studied in more patients with wAMD.","overall_status":"Unknown","phases":["PHASE1","PHASE2"],"study_type":"INTERVENTIONAL","sponsor":"Guangzhou Jiayin Biotech Ltd","enrollment":42,"countries":["China"],"start_date":"2023-10-12","completion_date":"2025-12-31","last_update_date":"2024-01-09","source_url":"https://clinicaltrials.gov/study/NCT06183814","editorial_summary":"A registered PHASE1, PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Unknown. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-25T01:25:30.378222+00:00","last_seen_at":"2026-09-25T06:20:47.789+00:00","metadata":{"sex":"ALL","acronym":null,"age_range":"50 Years","comparator":null,"organization":"Guangzhou Jiayin Biotech Ltd","interventions":["EXG102-031"],"registry_source":"ClinicalTrials.gov","outcome_measures":["Safety (Participants With Ocular and Non-ocular AEs (Adverse Events) and SAEs (Serious Adverse Events) — 24 weeks follo…","Safety (Participants With Ocular and Non-ocular AEs (Adverse Events) and SAEs (Serious Adverse Events) — 52 weeks follo…","Change From Baseline in BCVA (Best Corrected Visual Acuity) — 52 weeks following EXG102-031 administration","Change From Baseline in CRT (Central Retinal Thickness) — 52 weeks following EXG102-031 administration","Supplemental Injections (Annualized Rate of Supplemental Injections) — 52 weeks following EXG102-031 administration"],"design_description":"NON RANDOMIZED · SEQUENTIAL · TREATMENT · NONE","source_has_results":false},"controlled_terms":["Neovascular Age-related Macular Degeneration","EXG102-031"],"relevance_confidence":100,"source_quality_score":100,"freshness_score":65,"publication_state":"published","match_explanation":"Abstract contains controlled term: age-related macular degeneration.","quality_checked_at":"2026-09-25T06:20:59.355028+00:00","duplicate_cluster_key":"id:nct06183814","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2023-10-12 to 2025-12-31","comparator":null,"confidence":"structured-source","population":"ALL · 50 Years","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T06:20:47.913Z","intervention":["EXG102-031"],"participants":42,"study_design":"NON RANDOMIZED · SEQUENTIAL · TREATMENT · NONE","subject_scope":"Human clinical study registration","evidence_stage":"PHASE1, PHASE2","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["Safety (Participants With Ocular and Non-ocular AEs (Adverse Events) and SAEs (Serious Adverse Events) — 24 weeks follo…","Safety (Participants With Ocular and Non-ocular AEs (Adverse Events) and SAEs (Serious Adverse Events) — 52 weeks follo…","Change From Baseline in BCVA (Best Corrected Visual Acuity) — 52 weeks following EXG102-031 administration","Change From Baseline in CRT (Central Retinal Thickness) — 52 weeks following EXG102-031 administration","Supplemental Injections (Annualized Rate of Supplemental Injections) — 52 weeks following EXG102-031 administration"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"vision-aging","is_published":true,"match_reasons":["Abstract contains controlled term: age-related macular degeneration.","Source terminology contains: age-related macular degeneration.","Abstract supplies longevity context: age-related.","Study type is explicitly identified as INTERVENTIONAL."],"matched_fields":["abstract","controlled terminology","abstract context","study type"],"relevance_score":100,"intelligence_topics":{"name":"Vision ageing","slug":"vision-aging"}}],"content_sources":{"name":"ClinicalTrials.gov","homepage_url":"https://clinicaltrials.gov/"}},"canonical_url":"https://www.immortal.life/trials/42053","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}